The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
fda pi zhun imbruvica yong yu zhi liao tao xi bao lin ba liu
Pages: 711
Year: Issue:  12
Journal: World Clinical Drugs

Keyword:  套细胞淋巴瘤FDAImbruvica非霍奇金淋巴瘤细胞增殖临床不良反应肌肉骨骼疼痛呼吸困难http;
Abstract: <正>近日,FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤(MCL)。MCL是一种罕见的非霍奇金淋巴瘤,其发病率约占美国所有非霍奇金淋巴瘤病例的6%。通常MCL确诊时,肿瘤细胞已扩散至淋巴结、骨髓和其他器官。本品适用于既往至少接受过一次治疗的MCL患者,本品主要通过抑制肿瘤细胞增殖与扩散所需酶发挥治疗作用。本品是第三种获批用于治疗MCL的药品。此前,万珂(Velcade,2006)与来那度胺(Revlimid,2013)也获批用于治疗该病症。
Related Articles
No related articles found